NP
AGN

Ninepoint Partners’s Allergan plc AGN Stock Holding History

Ninepoint Partners’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,247
Closed -$1.07M – 140
2017
Q3 		$1.07M Buy
+5,247
New +$1.22M 0.08% 81

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Ninepoint Partners's AGN Position: Q4 2017 in Review

Ninepoint Partners sold out of Allergan plc (AGN) in Q4 2017, closing a stake of 5,247 shares — an estimated $1.07M sold.

Ninepoint Partners first reported a position in AGN in Q3 2017 and held it in 1 quarter. The position peaked at $1.07M in Q3 2017. 1,048 funds tracked by Wall St. Rank hold AGN as of Q4 2017.

  • Ninepoint Partners reported no remaining Allergan plc position as of Q4 2017 after selling out during the quarter.
  • Ninepoint Partners sold 5,247 Allergan plc shares in Q4 2017, an estimated $1.07M.
  • Ninepoint Partners first reported a position in Allergan plc in Q3 2017 and held it in 1 quarter.
  • Ninepoint Partners's Allergan plc position peaked at $1.07M in Q3 2017.
  • 1,048 funds tracked by Wall St. Rank held Allergan plc as of Q4 2017.

Based on Ninepoint Partners's 13F filing for Q4 2017, filed 12 Feb 2018.